Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000785 · ClinicalTrials.gov registry record
A Registry of Tuberculosis Cases in the CPCRA
A clinical trial of HIV Infections and Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1,509
- Enrollment target
- 13
- Study locations
NCT00000785: Completed study of HIV Infections and Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000785 is a study of HIV Infections and Tuberculosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,509 participants, above the 443-participant average among 542 other HIV Infections trials with a reported enrollment target (241% higher). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000785, a study of HIV Infections and Tuberculosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1,509 participants
- Enrollment target
- 13
- Study locations
Study Summary
PRIMARY: To estimate the proportion of tuberculosis patients in the CPCRA who have drug-resistant tuberculosis (TB) and to describe the patterns of drug resistance. SECONDARY: To compare drug resistance data on the Mycobacterium tuberculosis isolates of HIV-infected patients to those of HIV-uninfected patients who are being followed in the CPCRA. To assess the relationship of resistance data with geographic, demographic, and HIV and TB risk factor information. Geographic areas and demographic subgroups affected by the TB epidemic appear to be congruent and associated with the concurrent HIV epidemic. The total number of CPCRA patients who will develop, or who have experienced, confirmed TB is unknown. It is critical to determine the depth and breadth of the current problem of drug-resistant TB.
Conditions Studied
Study Locations (13)
New York
- Addiction Research and Treatment Corp - Brooklyn
- Clinical Directors Network of Region II - New York
- Harlem AIDS Treatment Group / Harlem Hosp Ctr - New York
- Bronx Lebanon Hosp Ctr - The Bronx
Michigan
- Comprehensive AIDS Alliance of Detroit - Detroit
- Henry Ford Hosp - Detroit
Colorado
- Denver CPCRA / Denver Public Hlth - Denver
District of Columbia
- Veterans Administration Med Ctr / Regional AIDS Program - Washington D.C.
Illinois
- AIDS Research Alliance - Chicago - Chicago
Louisiana
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med - New Orleans
New Jersey
- North Jersey Community Research Initiative - Newark
Oregon
- Portland Veterans Adm Med Ctr / Rsch & Education Grp - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,509 participants |
| Start Date | 1992-08 |
| Est. Completion | 1994-06 |
What the finished NCT00000785 record still lists
NCT00000785 is an observational study that tracks outcomes without assigning an intervention. Its 1,509 participants enrollment target places it among the larger protocols in the corpus, above the 443-participant average among 542 other HIV Infections trials with a reported enrollment target (241% higher).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00000785 lists 13 locations in 9 states (New York, Michigan, Colorado).
Frequently Asked Questions
What is clinical trial NCT00000785 about?
NCT00000785 is a clinical study titled "A Registry of Tuberculosis Cases in the CPCRA". PRIMARY: To estimate the proportion of tuberculosis patients in the CPCRA who have drug-resistant tuberculosis (TB) and to describe the patterns of drug resistance. SECONDARY: To compare drug resistance data on the Mycobacterium tuberculosis isolates of HIV-infected patients to those of HIV-uninfec...
What is the current status of trial NCT00000785?
This trial is currently completed. The enrollment target is 1,509 participants. The study started on 1992-08. Estimated completion is 1994-06.
What conditions does trial NCT00000785 study?
This clinical trial studies the following conditions: HIV Infections, Tuberculosis.
Who is sponsoring clinical trial NCT00000785?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000785 being conducted?
This trial has 13 study locations across Colorado, District of Columbia, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000785's enrollment target sits among peer trials
1,509 16th of 542 higher than 527 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia